Skip to main content
Journal cover image

Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study.

Publication ,  Journal Article
Shenoy, DA; Sloan, CE; Yanez, G; Sachs, E; Peairs, E; Cook, C; Matarangas, A; Brigman, B; Eward, WC; Visgauss, JD
Published in: Ann Surg Oncol
November 13, 2025

BACKGROUND: Financial toxicity in oncology, defined as the economic burden and psychosocial distress of cancer care, has been associated with poor clinical outcomes. Despite high projected treatment costs, data on financial toxicity in patients with sarcoma remain limited. This study aimed to characterize financial toxicity in survivors of sarcoma and to better inform screening practices for patients with rare cancers requiring complex, multidisciplinary treatment plans. METHODS: This retrospective cohort study surveyed patients with a diagnosis of trunk or extremity sarcomas between 2016 and 2024 (i.e., survivors of sarcoma). Patients were administered the COmprehensive Score for Financial Toxicity (COST) instrument, which has been validated with cancer patients. Scores ranged from 0 to 44. Financial toxicity was categorized into moderate-to-severe (score <26) and low-to-none (score ≥26) groups. Demographic and clinical variables were obtained from electronic medical records. Univariate logistic regression analyses were used to explore variables associated with financial toxicity. RESULTS: Among 205 participants, 77 % reported moderate-to-severe financial toxicity. The odds of financial toxicity were similar across insurance types, race, ethnicity, employment status, income, and geography. Patients were less likely to report financial toxicity if they had soft tissue sarcomas (compared with bone sarcomas; odds ratio, 0.43; 95% confidence interval, 0.18-0.98). CONCLUSION: Financial toxicity is highly prevalent among survivors of sarcoma. The widespread nature of this financial distress across different patient groups suggests that no specific population is disproportionately affected, underscoring the universal risk of financial toxicity. These findings support exploring universal financial toxicity screening for patients with sarcoma to facilitate timely interventions.

Duke Scholars

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

November 13, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shenoy, D. A., Sloan, C. E., Yanez, G., Sachs, E., Peairs, E., Cook, C., … Visgauss, J. D. (2025). Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study. Ann Surg Oncol. https://doi.org/10.1245/s10434-025-18732-5
Shenoy, Devika A., Caroline E. Sloan, Giussepe Yanez, Elizabeth Sachs, Emily Peairs, Chad Cook, Ariana Matarangas, Brian Brigman, William C. Eward, and Julia D. Visgauss. “Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study.Ann Surg Oncol, November 13, 2025. https://doi.org/10.1245/s10434-025-18732-5.
Shenoy DA, Sloan CE, Yanez G, Sachs E, Peairs E, Cook C, et al. Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study. Ann Surg Oncol. 2025 Nov 13;
Shenoy, Devika A., et al. “Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study.Ann Surg Oncol, Nov. 2025. Pubmed, doi:10.1245/s10434-025-18732-5.
Shenoy DA, Sloan CE, Yanez G, Sachs E, Peairs E, Cook C, Matarangas A, Brigman B, Eward WC, Visgauss JD. Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study. Ann Surg Oncol. 2025 Nov 13;
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

November 13, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis